Table 6.
Clinical and Treatment Characteristics for Patients With Extremely Short- and Long-Term Treatment Duration
| Variable | Extremely Short-Term Treatment Duration (n = 17) |
Extremely Long-Term Treatment Duration (n = 17) |
|---|---|---|
| Age, years | 45.6 (30.6-61.7) | 52.0 (25.2-83.3) |
| Stage at Initial Diagnosis | ||
| Stage IV | 1 (5.9) | 5 (29.4) |
| Stage I-III | 16 (94.1) | 12 (70.6) |
| Neo or Adjuvant Trastuzumab a | 5 (31.3) | 1 (8.3) |
| HR | ||
| Positive | 6 (35.3) | 12 (70.6) |
| Negative | 11 (64.7) | 5 (29.4) |
| DFI, years | 1.5 (0.0-10.3) | 0.5 (0-13.4) |
|
Sites at Initial Metastatic Diagnosis and/or
Recurrence |
2 (1-5) | 2 (1-4) |
|
Sites of Disease at Initial Metastatic Diagnosis and/or
Recurrence b |
||
| Soft tissuec | 9 (52.9) | 10 (58.8) |
| Bone | 6 (35.3) | 11 (64.7) |
| Liver | 9 (52.9) | 6 (35.3) |
| Lung | 10 (58.8) | 5 (29.4) |
| CNS | 0 (0) | 0 (0) |
| Other | 4 (23.5) | 1 (5.9) |
| Duration of First Metastatic Anti-HER2 Therapy, mo | 2.1 (1.5-2.8) | 49.5 (35.2-110.8) |
| Type of First Trastuzumab-Based Regimen | ||
| Monotherapy | 1 (5.9) | 2 (11.8) |
| Concomitant with endocrine therapy | 0 (0) | 1 (5.9) |
| Concomitant with chemotherapy | 16 (94.1) | 14 (82.4) |
| Concomitant with other anti-HER2 target agent | 0 (0) | 0 (0) |
| Best Clinical Response During First-Line Therapy | ||
| Complete response | 0 (0) | 1 (5.9) |
|
CNS Progression During First-Line Therapy (Non-
CNS Disease Controlled) |
0 (0) | 10 (58.8) |
|
Switch to Trastuzumab in Monotherapy or
Trastuzumab and Endocrine Furing First-Line Therapy |
0 (0) | 12 (70.6) |
Data are presented as median (range) or n (%).
Abbreviations: CNS = central nervous system; DFI = disease-free interval.
a
Proportion of stage I to III patients who received neo or adjuvant trastuzumab.
b
Proportion of patients does not add up to 100% because patients could have more than 1 site of recurrence.
c
Soft tissue includes: chest wall, breast, local and/or distant lymph nodes, or skin.